Patrick Henriet

Title: Patrick Henriet: Innovator in Cancer Treatment

Introduction

Patrick Henriet is a notable inventor based in Nivelles, Belgium. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. His work focuses on utilizing RNA interference (RNAi) technology to target galectin-1, a protein implicated in various cancers.

Latest Patents

Henriet holds a patent for the "Use of a galectin-1-targeted RNAi-based approach for the treatment of cancer." This invention relates to an RNAi molecule designed to reduce the expression of galectin-1, specifically using sequences from SEQ ID NOs: 1-33, with a preference for SEQ ID NO: 2, 3, or 4. The patent outlines its application as a medicament for treating or delaying the progression of several types of cancer, including glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer, and non-Hodgkin's lymphoma. Additionally, it discusses methods for reducing tumor cell migration and enhancing the efficacy of various cancer therapies.

Career Highlights

Throughout his career, Patrick Henriet has worked with prestigious institutions, including Université Libre de Bruxelles and Université Catholique de Louvain. His research has contributed to advancements in cancer therapies, particularly through the application of RNAi technology.

Collaborations

Henriet has collaborated with notable colleagues such as Isabelle Camby and Florence Lefranc. Their joint efforts have furthered the understanding and treatment of cancer, showcasing the importance of teamwork in scientific research.

Conclusion

Patrick Henriet's innovative work in cancer treatment through RNAi technology highlights his commitment to advancing medical science. His contributions are paving the way for new therapeutic approaches in oncology.